Please login to the form below

Not currently logged in
Email:
Password:

Takeda extends its operations

Takeda, Japan's largest pharma company, is to set up sales and marketing operations in Spain, and expand its promotional activities in the Republic of Ireland

Takeda, Japan's largest pharma company, is to set up sales and marketing operations in Spain, and expand its promotional activities in the Republic of Ireland to cover the entire country.

The company now has sales and marketing divisions in eight European countries. In addition to Spain and Ireland, there are wholly-owned subsidiaries in France, UK, Italy, Germany, Austria and Switzerland.

Subsidiary, Takeda Farmacéutica España SA, will start promoting Blopress (candesartan cilexetil), an antihypertensive therapy known as Amias in the UK, and Actos (pioglitazone HCl) one of Takeda's two therapies for Type II diabetes.

In the Republic of Ireland, Takeda expanded promotional activities for Actos in January this year, having been active in a specific part of the country only.

Eric Brunn, CEO of Takeda Pharmaceutical Europe, Takeda's UK subsidiary said: "We are pleased with the expansion of geographical coverage in Spain, one of the most important markets in Europe, and also the nationwide coverage in the Republic of Ireland. We will actively introduce products from our portfolio into these two countries."

In 2004, Takeda received approval for Blopress to be used in the treatment of chronic heart failure (CHF). Candesartan is marketed worldwide as Blopress (or Amias) by Takeda and under the brand name of Atacand by AstraZeneca in more than 70 countries.

30th March 2009

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics